drugset / Trial / NCT00379730

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00379730

Phase 1 Completed 90 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2006-03-21
Primary completion
Completion
2007-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified 20 mg